A study published in June 2021, introduced a lipid nanoparticle-delivered CRISPR-Cas9 genome editing tool to treat individuals affected by transthyretin amyloidosis (ATTR amyloidosis), a life-threatening disease caused by progressive accumulation of misfolded transthyretin (TTR) [560]. Here, TTR is linked to Familial transthyretin-related amyloidosis.